research use only

Bemnifosbuvir Hemisulfate (AT-527) SARS-CoV inhibitor

Name: Bemnifosbuvir Hemisulfate (AT-527)
Brand: Selleck Chemicals
SKU: E1013
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E1013

Bemnifosbuvir Hemisulfate (AT-527, RG-6422, RO 7496998) is a hemi-sulfate salt of AT-511, which is a potent inhibitor of SARS-CoV-2 with an EC90 of 0.47 μM.

Chemical Structure

Molecular Weight: 630.55

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: E101301 DMSO]100 mg/mL]false]Water]100 mg/mL]false]Ethanol]100 mg/mL]false Purity: 99.37%

99.37

Related Targets	Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease HIV Protease Influenza Virus β-lactamase Integrase HBV CMV Neuraminidase HCV HSV RSV Enterovirus Thioredoxin Reductase 3C-Like Protease Ribosomal Peptidyl Transferase HPV
Related Products	Molnupiravir (EIDD-2801) Nirmatrelvir (PF-07321332) EIDD-1931 (NHC)

Chemical Information, Storage & Stability

Molecular Weight	630.55	Formula	C₂₄H₃₃FN₇O₇P._1/2H₂O₄S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	2241337-84-6	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	RG-6422, RO 7496998			Smiles	CNC1=C2N=C[N](C3OC(CO[P](=O)(NC(C)C(=O)OC(C)C)OC4=CC=CC=C4)C(O)C3(C)F)C2=NC(=N1)N.O[S](O)(=O)=O

Solubility

In vitro
Batch:

DMSO : 100 mg/mL ( (158.59 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 100 mg/mL

Ethanol : 100 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	SARS-CoV-2 ^[1] 0.47 μM(EC90)
In vitro	Bemnifosbuvir Hemisulfate (AT-527) is the free base of AT-511. This compound inhibits replication of several human coronaviruses, such as HCoV-229E, HCoV-OC43, SARS-CoV in Huh-7 cells and HCoV-229E in BHK-21 cells. It can also inhibits SARS-CoV-2 replication in primary human airway epithelial (HAE) cells. In HBE and HNE cells, it can promote the host cells to form the pharmacologically active TP, AT-9010, to inhibit virus replication.^[1]
In vivo	After oral administration of Bemnifosbuvir Hemisulfate (AT-527) in nonhuman primates (NHPs), T-273 has the longest MRT at all dose levels, which indicate the long half-life of the active TP formed intracellularly. This compound is preferentially delivered to the liver, the target organ for HCV infection.^[1]
References	https://pubmed.ncbi.nlm.nih.gov/33558299/ https://pubmed.ncbi.nlm.nih.gov/34725982/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05618314	Recruiting	Healthy Volunteer\|Renal Impairment	Atea Pharmaceuticals Inc.	October 17 2022	Phase 1
NCT05137626	Completed	Healthy Volunteers Study	Atea Pharmaceuticals Inc.\|Hoffmann-La Roche	November 3 2021	Phase 1
NCT04309734	Withdrawn	Hepatitis C\|Hepatitis C Chronic\|Chronic Hepatitis C\|Hepatitis C Virus Infection\|HCV Infection	Atea Pharmaceuticals Inc.	October 2021	Phase 1\|Phase 2
NCT04877769	Completed	Healthy Volunteer Study	Atea Pharmaceuticals Inc.\|Hoffmann-La Roche	April 25 2021	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):